HU9601193D0 - Substituted di- and tripeptide inhibitors of protein:farnesyl transferase - Google Patents

Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Info

Publication number
HU9601193D0
HU9601193D0 HU9601193A HU9601193A HU9601193D0 HU 9601193 D0 HU9601193 D0 HU 9601193D0 HU 9601193 A HU9601193 A HU 9601193A HU 9601193 A HU9601193 A HU 9601193A HU 9601193 D0 HU9601193 D0 HU 9601193D0
Authority
HU
Hungary
Prior art keywords
protein
substituted
farnesyl transferase
tripeptide inhibitors
tripeptide
Prior art date
Application number
HU9601193A
Other languages
Hungarian (hu)
Other versions
HUT75308A (en
Inventor
Gary Louis Bolton
Mark Wallace Creswell
John Cooke Hodges
Michael William Wilson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HU9601193D0 publication Critical patent/HU9601193D0/en
Publication of HUT75308A publication Critical patent/HUT75308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HU9601193A 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase HUT75308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14873593A 1993-11-05 1993-11-05
US30330194A 1994-09-13 1994-09-13

Publications (2)

Publication Number Publication Date
HU9601193D0 true HU9601193D0 (en) 1996-07-29
HUT75308A HUT75308A (en) 1997-05-28

Family

ID=26846110

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9601193A HUT75308A (en) 1993-11-05 1994-10-12 Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Country Status (10)

Country Link
EP (1) EP0730605A1 (en)
JP (1) JP3597863B2 (en)
KR (1) KR100362338B1 (en)
AU (1) AU681454B2 (en)
CA (1) CA2170766A1 (en)
FI (1) FI961819A0 (en)
HU (1) HUT75308A (en)
NO (1) NO961814L (en)
NZ (1) NZ275691A (en)
WO (1) WO1995012612A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU95104898A (en) * 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Imedazole containing inhibitors of ferneside proteintansferase, and method of treatment diseases related therewith
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU700175B2 (en) * 1994-09-29 1998-12-24 Merck & Co., Inc. Thiol-free inhibitors of farnesyl-protein transferase
US5652257A (en) * 1994-09-29 1997-07-29 Merck & Co., Inc. Heterocycle-containing inhibitors of farnesyl-protein transferase
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972984A (en) * 1995-06-06 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2736641B1 (en) * 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
EA199801031A1 (en) * 1996-05-22 1999-06-24 Варнер-Ламберт Компани PROTEINFARNESILTRANSFERASE INHIBITORS
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
DE69728165T2 (en) * 1996-12-17 2005-01-20 Warner-Lambert Co. Llc CYCLOALKYL INHIBITORS OF PROTEIN FARNESYL TRANSFERASE
FR2757855B1 (en) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6423689B1 (en) 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
BR9907170A (en) 1998-04-02 2000-12-26 Reynolds Tobacco Co R Pharmaceutical compositions and methods for use
US6369034B1 (en) 1998-04-27 2002-04-09 Warner-Lambert Company Functionalized alkyl and alenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
BR9916004A (en) 1998-12-10 2001-10-02 Hoffmann La Roche Pro-collagen proteinase and c inhibitors
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
FR2796641B1 (en) 1999-07-22 2001-09-21 Aventis Pharma Sa NOVEL PROCESS FOR THE PREPARATION OF BENZOPERHYDROISOINDOLE COMPOUNDS
JPWO2005044780A1 (en) * 2003-11-10 2007-05-17 杏林製薬株式会社 Aminocarboxylic acid derivatives and their addition salts and S1P receptor modulators
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
SI2010528T1 (en) 2006-04-19 2018-02-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (en) 2007-01-10 2014-12-31 Msd Italia Srl Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
MX2009009304A (en) 2007-03-01 2009-11-18 Novartis Ag Pim kinase inhibitors and methods of their use.
CA2685967A1 (en) 2007-05-21 2008-11-21 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5452237B2 (en) 2008-02-07 2014-03-26 杏林製薬株式会社 Therapeutic or prophylactic agent for inflammatory bowel disease comprising an amino alcohol derivative as an active ingredient
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
PE20121172A1 (en) 2009-10-14 2012-09-05 Merck Sharp & Dohme PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
BR112012023021A2 (en) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (en) 2011-04-21 2015-06-12 Piramal Entpr Ltd
MY172013A (en) 2011-10-26 2019-11-12 Allergan Inc Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
MX363243B (en) 2012-11-28 2019-03-14 Merck Sharp & Dohme Compositions and methods for treating cancer.
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
ES2676734T3 (en) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Heteroatomic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
JP6854762B2 (en) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (en) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
MX2019012233A (en) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anti-sirp alpha antibodies.
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072033A1 (en) * 1991-06-28 1992-12-29 Jackson B. Gibbs Non-substrate inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
FI961819A (en) 1996-04-29
JPH09504547A (en) 1997-05-06
NO961814D0 (en) 1996-05-03
FI961819A0 (en) 1996-04-29
CA2170766A1 (en) 1995-05-11
HUT75308A (en) 1997-05-28
AU7976094A (en) 1995-05-23
EP0730605A1 (en) 1996-09-11
JP3597863B2 (en) 2004-12-08
KR100362338B1 (en) 2003-04-08
WO1995012612A1 (en) 1995-05-11
AU681454B2 (en) 1997-08-28
NZ275691A (en) 1998-03-25
NO961814L (en) 1996-05-06

Similar Documents

Publication Publication Date Title
HU9601193D0 (en) Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
EP0696593A3 (en) Inhibitors of farnesyl protein transferase
EP0535730A3 (en) Inhibitors of farnesyl protein transferase
EP0535731A3 (en) Inhibitors of farnesyl protein transferase
IL124197A (en) Inhibitors of farnesyl protein transferase
IL126833A0 (en) Inhibitors of protein farnesyl transferase
EP0918771A4 (en) Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
AU4645593A (en) Inhibitors of farnesyl protein transferase
HUP0004148A3 (en) Inhibitors of farnesyl protein transferase
AU5918494A (en) Heterocyclic inhibitors of farnesyl protein transferase
EP0547669A3 (en) Inhibitors of farnesyl protein transferase
HU9500934D0 (en) Imidazole-containing inhibitors of farnesyl protein transferase
AU5772698A (en) Inhibitors of farnesyl protein transferase
PL308553A1 (en) Inhibitors of farnesil-protein transferase
EP1027042A4 (en) Inhibitors of farnesyl protein transferase
EP0520823A3 (en) Non-substrate peptide inhibitors of farnesyl protein transferase
EP0547670A3 (en) Inhibitors of farnesyl protein transferase
AU5164898A (en) Thioproline-containing inhibitors of farnesyl protein transferase
EP0547672A3 (en) Inhibitors of farnesyl protein transferase
ZA985203B (en) Compounds useful for inhibition of farnesyl protein transferase
HUP9904056A3 (en) Substituted benzocycloheptapyridine derivatives useful as inhibitor of farnesyl protein transferase and use thereof
EP0547671A3 (en) Inhibitors of farnesyl protein transferase
GB9223246D0 (en) Inhibitors of farnesyl protein transferase
GB9223250D0 (en) Inhibitors of farnesyl protein transferase
AU4329397A (en) Semipeptoid farnesyl protein transferase inhibitors and analogs thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees